Posted by Michael Wonder on 21 Jul 2016
pERC issues final recommendation for Imbruvica (ibrutinib)
19 July 2016 - Canada's pCODR Expert Review Committee has issued a final recommendation for Janssen's ibrutinib for patients with mantle cell lymphoma.
The ERC has recommended the reimbursement of ibrutinib for the treatment of patients with relapsed/refractory mantle cell lymphoma conditional upon its cost effectiveness being improved to an acceptable level. Treatment should be for patients with a good performance status and until disease progression or unacceptabel toxicity.
